[ RECIPIENT ENTITY RECORD ]

Inhibrx

VERIFIED NODE ID: 001730 · inhibrx
R TARGET NODE — CAPITAL RECIPIENT
Inhibrx
Company United States
Recipient Type
Company
Primary Jurisdiction
United States
Registration Status
ACTIVE
Entity Intelligence [ R ]
Legal Name Inhibrx
Entity Type Company
Jurisdiction United States
Recipient Intelligence Summary

Inhibrx is a clinical-stage biopharmaceutical company focused on the development of novel biologic therapeutics for oncology and rare diseases. Based in California, the firm’s technology platform enables the creation of complex protein therapies. It was a notable recipient of institutional healthcare capital through a high-value pharmaceutical takeover.

Capital Influx Log (Transactions)
Date Type Amount
22 May 2026 EQUITY $1.7B